Aurobindo Pharma recalls 88600 vials of Lidocaine injections from US

Lidocaine HCl injection is a medication used for local or regional anaesthesia to perform certain surgeries and procedures.

New Delhi: Aurobindo Pharma Ltd has initiated the recall of 88,600 vials of Lidocaine HCl Injection, USP 1 % 50 mg/5 mL (10 mg/mL) from USA market as one of the vials contained a strand of hair, the US Food and Drug Administration said.

According to a notification put up by the US Drug regulator in its website, these vials were manufactured in India for Auro Medics Pharna LLC.

Read Also: Lupin, Aurobindo Pharma recalls multiple lots of BP drug including VALSARTAN

"Reason for Recall: Presence of Particulate Matter: One vial was found to contain a hair," it said.

Lidocaine HCl injection is a medication used for local or regional anaesthesia to perform certain surgeries and procedures.

The Product is being held at a distributor site in Mexico, Asheboro and Charlotte, North Carolina, and Santa Teresa, New Mexico and not further distributed in the US Market, the FDA notification said.

Read Also: Aurobindo Pharma acquires 7 oncology products worth over Rs 2100 crore from US firm

Aurobindo Pharma USA Inc has recently initiated recalling some lots of Valsartan tablets in various strengths due to "the presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the active pharmaceutical ingredient (API) which used to manufacture the product."

Valsartan Tablets USP are indicated to control high blood pressure and used for the treatment of heart failure.

Read Also: Aurobindo Pharma facility manufacturing Sterile Injections fails to establish sterility, says USFDA